Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Baxter International Stock Up 1.2 %
Shares of NYSE:BAX traded up $0.68 during midday trading on Friday, hitting $58.59. The stock had a trading volume of 2,448,400 shares, compared to its average volume of 3,262,792. Baxter International has a 12 month low of $57.49 and a 12 month high of $89.70. The company has a quick ratio of 1.33, a current ratio of 2.01 and a debt-to-equity ratio of 1.83. The business's 50-day simple moving average is $66.20 and its 200-day simple moving average is $74.61. The company has a market cap of $29.51 billion, a P/E ratio of 29.30, a PEG ratio of 1.60 and a beta of 0.60.
Baxter International (NYSE:BAX - Get Rating) last posted its earnings results on Thursday, July 28th. The medical instruments supplier reported $0.87 earnings per share for the quarter, hitting analysts' consensus estimates of $0.87. The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.88 billion. Baxter International had a return on equity of 21.75% and a net margin of 7.12%. The company's revenue was up 20.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.80 earnings per share. On average, sell-side analysts forecast that Baxter International will post 3.62 earnings per share for the current fiscal year.
Baxter International Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Monday, October 3rd. Shareholders of record on Friday, September 2nd will be paid a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a yield of 1.98%. The ex-dividend date of this dividend is Thursday, September 1st. Baxter International's payout ratio is 58.00%.
Analyst Ratings Changes
A number of equities analysts have recently commented on the stock. Wells Fargo & Company lowered shares of Baxter International from an "overweight" rating to an "equal weight" rating and set a $71.00 price objective for the company. in a research report on Friday, June 24th. The Goldman Sachs Group reaffirmed a "sell" rating and set a $60.00 price target (down previously from $70.00) on shares of Baxter International in a research report on Wednesday. Deutsche Bank Aktiengesellschaft dropped their price target on Baxter International from $99.00 to $69.00 in a research note on Friday, July 29th. Raymond James lowered their price target on Baxter International from $96.00 to $85.00 in a research report on Friday, April 29th. Finally, Morgan Stanley dropped their price objective on Baxter International from $86.00 to $72.00 and set an "overweight" rating on the stock in a research report on Friday, July 29th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $79.29.
